ASX Announcements


 
    Final Director's Interest Notice  
 
    Ceasing to be a substantial holder  
 
    2018 Year-end Business Update  
 
    Larry Glass to retire as a director and continue as CSO  
 
    Presentation at AusBiotech Invest and Partnering 2018  
 
    Appendix 4C - quarterly  
 
    Trofinetide ex-North America exclusive negotiation period  
 
    Neuren and ACADIA hold Rett syndrome SAB meeting  
 
    Change of Director's Interest Notice  
 
    FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID  
 
    Investor presentation, 6 September 2018  
 
    Half Yearly Report and Accounts  
 
    Neuren and Lanstead agree to pause settlements for 120 days  
 
    Appointment of auditor  
 
    Neuren receives initial payment of US$10 million from ACADIA  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Investor update  
 
    Neuren and ACADIA announce agreement for North America  
 
    Appendix 4C - quarterly  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Neuren announces new appointments to the board of directors  
 
    Results of Meeting  
 
    Chairman's Address at 2018 Annual Shareholders' Meeting  
 
    Change of Director's Interest Notice  
 
    Final share buy-back notice - Appendix 3F  
 
    Announcement of buy-back - Appendix 3C  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Neuren announces investment and exclusive negotiation period  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    Appendix 4C - quarterly  
 
    First patent in Japan granted for Neuren's trofinetide  
 
    Full Year Statutory Accounts  
 
    Disclosure under Listing Rule 4.3D  
 
    S&P DJ Indices Announces March Quarterly Rebalance  
 
    Preliminary Final Report  
 
    Appendix 4C - quarterly  
 
    Final Director's Interest Notice  
 
    Non-executive director retirement  
 
    Change in substantial holding  
 
    Neuren announces new US patent to be granted for NNZ-2591  
 
    Consolidation/Split - NEU  
 
    Notification under Listing Rule 7.20 of share reorganisation  
 
    Appendix 4C - quarterly  
 
    Neuren FDA meeting confirms Phase 3 plan for Rett syndrome  
 
    Investor presentation, 6 October 2017  
 
    Presentations and publication for Rett syndrome trials  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Neuren reports 2017 half-year results  
 
    Half Yearly Report and Accounts  
 
    Notice of special meeting of shareholders  
 
    Appendix 4C - quarterly  
 
    Becoming a substantial holder  
 
    Neuren granted Type B Meeting with FDA for Rett syndrome  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Results of Meeting  
 
    2017 AGM Chairman's Address  
 
    Neuren secures funding for key activities for Rett syndrome  
 
    Response to ASX Price Query  
 
    Trading Halt  
 
    Investor presentation, 2 June 2017  
 
    Neuren announces grant of two new patents to 2032  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Response to Appendix 4C Query  
 
    Appendix 4C - quarterly  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    Neuren receives $1 million R&D Tax Incentive  
 
    Investor presentation, 3 April 2017  
 
    Full Year Statutory Accounts  
 
    Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome  
 
    Trading Halt  
 
    S&P DJ Indices Announces March Quarterly Rebalance  
 
    Preliminary Final Report  
 
    Investor presentation, 2 February 2017  
 
    Appendix 4C - quarterly  
 
    Neuren completes Phase 2 trial in pediatric Rett syndrome  
 
    Results of Meeting  
 
    Investor presentation, 25 November 2016  
 
    Notice of special meeting of shareholders  
 
    Neuren completes enrolment in Rett syndrome Phase 2 trial  
 
    Appendix 4C - quarterly  
 
    Neuren receives $0.9m from exercise of last expiring options  
 
    Appendix 3B  
 
    Change of Melbourne Registry Address Notification  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Half Yearly Report and Accounts  
 
    Neuren expands Phase 2 Rett syndrome pediatric trial  
 
    Appendix 4C - quarterly  
 
    Neuren presents at Rettsyndrome.org 2016 Research Symposium  
 
    Grant of new patent for Autism Spectrum Disorders  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Change of Director's Interest Notice  
 
    Presentation at 6th Annual TBI Conference, Washington DC  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 4C - quarterly  
 
    Neuren Shareholder Update  
 
    Results of Phase 2 trial in moderate to severe TBI  
 
    Trading Halt  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    First subject commences Neuren's Rett syndrome Phase 2 trial  
 
    Neuren reports 2015 full-year financial results  
 
    Appendix 4E and Financial Report 31 December 2015  
 
    Appendix 4C - quarterly  
 
    Neuren Investor Presentation, 11 January 2016  
 
    Neuren Shareholder Update, January 2016  
 
    Appendix 3B  
 
    Trofinetide successful in Phase 2 trial in Fragile X  
 
    Trading Halt  
 
    Grant of composition patent in Europe for Neuren's NNZ-2591  
 
    Corporations Act Notice  
 
    Appendix 3B  
 
    Shareholders provide further support for Rett syndrome  
 
    Neuren completes enrolment in INTREPID clinical trial  
 
    Appendix 4C - quarterly  
 
    IRSF confirms financial support for Neuren's clinical trials  
 
    New US patent covering use of trofinetide for Rett syndrome  
 
    Neuren provides update on Fragile X and INTREPID trials  
 
    Half Yearly Report and Accounts 30 June 2015  
 
    trofinetide confirmed as INN for Neuren's NNZ-2566  
 
    Neuren confirms orphan drug designations in Europe  
 
    Investor presentation, 31 July 2015  
 
    Appendix 4C - quarterly  
 
    Neuren reports progress in orphan drug programs  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    Appendix 3B  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to shareholders  
 
    Neuren receives response to request for Breakthrough Therapy  
 
    Neuren reports 2014 full-year financial results  
 
    Preliminary Final Report and 2014 full year accounts  
 
    FDA grants Neuren Orphan Drug designation for Rett syndrome  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Updated Share Trading Policy  
 
    Neuren announces trofinetide as proposed INN for NNZ-2566  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    Investor Presentation, 8 January 2015  
 
    Response to ASX Price Query  
 
    Neuren submits Orphan Drug/Breakthrough Therapy applications  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Investor presentation, 27 November 2014  
 
    Appendix 3B  
 
    Neuren successful in Rett syndrome Phase 2 trial  
 
    Trading Halt  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Issue of long term incentives  
 
    Neuren to release Rett Syndrome trial results in November  
 
    Enrolment commences in Neuren's Concussion Phase 2 trial  
 
    Investor presentation, 4 September 2014  
 
    Appendix 3B  
 
    Neuren reports 2014 half-year financial results  
 
    Half Yearly Report and Accounts  
 
    Appendix 3B  
 
    Neuren advances NNZ-2591 towards IND application  
 
    Appendix 3B  
 
    Appendix 4C - quarterly  
 
    US$3m increase to US Army grant and INTREPID outlook update  
 
    Neuren receives ethics approval to start Concussion trial  
 
    Neuren completes enrolment in Phase 2 trial in Rett Syndrome  
 
    Appendix 3B  
 
    Neuren appoints CMC expert to leadership team  
 
    Neuren receives new US patent for NNZ-2591  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Neuren presents at International Meeting for Autism Research  
 
    Appendix 3B  
 
    Appendix 3B  
 
    AGM Results of Meeting  
 
    Chairman's AGM Address to Shareholders  
 
    Appendix 4C - quarterly  
 
    Presentation at Morgans Emerging Companies Conference  
 
    Notice of Annual General Meeting - Proxy Form  
 
    Appendix 3B  
 
    2013 Annual Report  
 
    ZSP S and P DJ Indices Announces March Quarterly Rebalance  
 
    Neuren reports financial results for 2013  
 
    Preliminary Final Report and audited Financial Statements  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Neuren reports progress in NNZ-2566 clinical trial programs  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Neuren Share Purchase Plan raises $2 million  
 
    Ceasing to be a substantial holder  
 
    Investor presentation, 19 November 2013  
 
    Appendix 3B  
 
    Change in substantial holding  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Share Purchase Plan record date  
 
    SPP Certification  
 
    Appendix 3B  
 
    Becoming a substantial holder  
 
    Share Purchase Plan offer documents  
 
    Orphan drug designation from FDA for NNZ-2566 in Fragile X  
 
    Section 708A(5)e Notice  
 
    Appendix 3B  
 
    Placement of $21.5m to accelerate execution of strategy  
 
    Neuren receives Fast Track designation for Fragile X  
 
    Trading Halt  
 
    Appendix 3B  
 
    Response to ASX Price Query  
 
    Investor presentation  
 
    Neuren data presented at Fragile X Foundation meeting  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Neuren opens new IND for NNZ-2566 in Fragile X Syndrome  
 
    Final Director's Interest Notice  
 
    Neuren announces changes to its leadership team  
 
    Half Yearly Report and Accounts  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Response to social media commentary re Rett trial  
 
    Trading Halt Request  
 
    Trading Halt  
 
    Investor presentation July 2013  
 
    Appendix 3B Option Exercise  
 
    Results in Fragile X Model with NNZ 2591  
 
    Response to ASX Price Query  
 
    Neuren receives two new patents  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B Option Exercise amended  
 
    Appendix 3B Option Exercise  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B Option Exercise  
 
    Response to ASX Price Query Letter  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B Option Exercise  
 
    FDA Fast Track granted for NNZ2566 Rett program  
 
    Change of Director's Interest Notice  
 
    Appendix 3B Equity Performance Rights  
 
    Appendix 3B Loan Funded Shares  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    CFO appointment  
 
    Final Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Appendix 3B Exercise of Options  
 
    Lapse of Unlisted Options  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Investor Presentation May 2013  
 
    Results of Meeting  
 
    CEO Presentation to AGM  
 
    Chairman's Address to AGM  
 
    Response to ASX Price Query Letter  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Shareholder Update  
 
    Ceasing to be a substantial holder  
 
    Annual Report to shareholders  
 
    Preliminary Final Report  
 
    Initial Director's Interest Notice  
 
    Dr Richard Treagus joins Neuren Board  
 
    Neuren appoints Nancy Jones SD Clinical & Medical Affairs  
 
    Neuren IND open for Rett Phase II trial  
 
    Appendix 3B  
 
    Neuren TAP Conference presentation and Fragile X results  
 
    Neuren completes Phase I NNZ2566 study/files Phase II IND  
 
    Amended 2 - Change in substantial holding  
 
    Amended Change in substantial holding  
 
    Change in substantial holding  
 
    Response to ASX Price Query  
 
    NNZ2566 selected as Windhover Top 10 Neuroscience Project  
 
    Half Yearly Report and Accounts  
 
    Neuren appoints Joe Horrigan VP Clinical and Medical Affairs  
 
    NNZ2566 Rationale in ASDs  
 
    Neuren awarded Rett Syndrome trial grant  
 
    Final Director`s Interest Notice  
 
    Initial Director`s Interest Notice  
 
    Results of Meeting  
 
    CEO`s address to AGM  
 
    Neuren announces cancer xenograft testing results  
 
    Change in substantial holding  
 
    Rett Syndrome pre-IND meeting held with FDA  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B (exercise of options)  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Response to ASX Price Query  
 
    Neuren 2011 Annual Report  
 
    Initial Director`s Interest Notice  
 
    Neuren appoints Bruce Hancox to board of directors  
 
    Neuren presentation to Arrowhead TBI Conference  
 
    Neuren 2011 Preliminary Final Report  
 
    Neuren to proceed with oral NNZ2566 trial  
 
    Change in substantial holding  
 
    Response to ASX Price Query  
 
    Neuren Completes Phase II trial Cohort 2  
 
    Appendix 3B (exercise of options)  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Appendix 3B (amendment)  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Appendix 3B  
 
    Response to ASX Price Query  
 
    Half Yearly Report and Accounts  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Neuren places $3m of rights issue shortfall  
 
    Appendix 4C - quarterly  
 
    NEU Broker Presentation July 2011  
 
    Neuren CEO presentation to Bioshares Biotech Summit  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Appendix 3B  
 
    Results of Neuren Rights Issue  
 
    Neuren Confirms Despatch of Rights Issue Offer Documents  
 
    Appendix 3B  
 
    CEO presentation to AusBiotech New York  
 
    Rights Issue Eligible Shareholder Notice  
 
    Change in substantial holding  
 
    Rights Issue Notice to Foreign Shareholders  
 
    Rights Issue Notice to Optionholders  
 
    Rights Issue Notice under Section 708AA  
 
    Appendix 3B (renounceable rights issue)  
 
    Neuren Rights Issue Letter of Offer (Australian residents)  
 
    Neuren Rights Issue Offer Document (NZ residents)  
 
    Neuren announces Renounceable Rights Issue  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Neuren completes placement and converts remaining note  
 
    Appendix 3B (options)  
 
    Appendix 3B (shares)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Results of Annual Meeting  
 
    Results of Special Meeting  
 
    Neuren CEO Presentation to AGM  
 
    Neuren reduces outstanding convertible note principal  
 
    Neuren`s Perseis selects lead antibodies  
 
    Notice of Special Shareholders Meeting/Proxy Form  
 
    Neuren Completes Phase II trial Cohort 1  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Becoming a substantial holder  
 
    Neuren Announces Private Placement and Rights Issue  
 
    Trading Halt  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Annual Report to shareholders  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Response to ASX Price Query  
 
    Notice of Special Shareholders Meeting  
 
    Preliminary Final Report  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Lapse of unquoted options  
 
    Appendix 3B  
 
    Appendix 3B (amended)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Securities Trading Policy  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Neuren Initiates NNZ2566 Oral Formulation Development  
 
    Neuren Completes Additional Phase I Study for TBI  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Lapse of unquoted options  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Half Yearly Report and Accounts  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    SpringTree becomes a substantial shareholder  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B (options)  
 
    Appendix 3B (shares)  
 
    Appendix 3B  
 
    Results of Meeting  
 
    CEO Presentation to AGM  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Neuren Starts Phase II Trial of NNZ2566  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appendix 3B (convertible note)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B (options)  
 
    Appendix 3B (shares)  
 
    Lapse of unquoted options  
 
    Annual Report to shareholders  
 
    Appendix 3B - ESOP  
 
    Appendix 3B (convertible note)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Grant funding for TFF oncology program  
 
    Trial of Second Neuren Drug Motiva to be Initiated  
 
    Preliminary Final Report  
 
    Appendix 3B (convertible note)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B (options)  
 
    Appendix 3B (shares)  
 
    Ceasing to be a substantial holder  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Cato strategic partnership and appoints US CMO  
 
    Appendix 3B  
 
    Change in substantial holding  
 
    Change of Director`s Interest Notice  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B (options)  
 
    Appendix 3B (shares)  
 
    Neuren Completes Shareholder Approved Funding  
 
    Results of Special Shareholders Meeting  
 
    Initial Director`s Interest Notice  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Notice of Special Shareholders Meeting  
 
    Dr John Holaday joins Neuren Board  
 
    Appendix 3B (options)  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B (notes)  
 
    Appendix 3B (shares)  
 
    Neuren Arranges up to AU$7.8m in New Funding  
 
    Reinstatement to Official Quotation  
 
    Suspension from Official Quotation  
 
    Trading Halt  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Appendix 3B  
 
    Reponse to Price Query  
 
    Half Year Report and Accounts  
 
    Appendix 3B  
 
    Neuren raises NZ$1 million through SPP  
 
    Neuren SPP section 708A notice  
 
    SPP NZ Certification  
 
    Neuren NNZ-2566 Development Overview  
 
    Neuren Share Purchase Plan  
 
    Neuren Chairmans SPP Letter  
 
    SPP terms update  
 
    Neuren Share Purchase Plan  
 
    Ceasing to be a substantial holder  
 
    Neuren obtains further US$14m US Army funding  
 
    Results of Meeting  
 
    Presentation to AGM  
 
    Chairman`s Address to Shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Neuren Progresses Cancer Program  
 
    Trading Halt  
 
    Response to ASX Price Query  
 
    Trading Halt  
 
    Lapse of unquoted options  
 
    Annual Report to shareholders  
 
    Final Director`s Interest Notice  
 
    Preliminary Final Report  
 
    Neuren Strategy Update  
 
    Respone to ASX price query  
 
    Trading Halt  
 
    Change of Director`s Interest Notice  
 
    Neuren Announces Glypromate Trial Preliminary Results  
 
    Phase 3 trial data collection completed  
 
    Appendix 3B  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Neuren raises $2m through underwritten SPP  
 
    Appendix 3B  
 
    US Army to provide additional NNZ2566 trial funding  
 
    Half Yearly Report and Accounts  
 
    Results of Special Shareholders` Meeting  
 
    Neuren extends SPP closing date  
 
    Neuren signs cancer license and collaboration agreement  
 
    NZ Securities Act certification for SPP  
 
    Share Purchase Plan letter to eligible shareholders  
 
    Notice under section 708A(5)(e) of the Corporations Act  
 
    Change in substantial holding  
 
    Notice of Special Meeting  
 
    Neuren Share Purchase Plan  
 
    Appendix 3B  
 
    Neuren raises a minimum of $3 million  
 
    Reinstatement to Official Quotation  
 
    Voluntary Suspension extended  
 
    Suspension from Official Quotation  
 
    Trading Halt  
 
    Glypromate and NNZ 2566 in Top 10 Neuroscience Projects  
 
    NEU Completes Glypromate Phase 3 Recruitment  
 
    Neuren to get early results from Glypromate trial  
 
    Results of Meeting  
 
    CEO presentation to AGM  
 
    Response to ASX Query re: Appendix 4C  
 
    Positive interim safety analysis for Glypromate  
 
    Quarterly Update to Shareholders April 2008  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to shareholders  
 
    Co-CEOs remuneration packages  
 
    Appendix 4E Preliminary Final Report  
 
    Appendix 3B  
 
    Form 604  
 
    Becoming a substantial holder  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Rights issue raises $7.1m and notes convert  
 
    Substantial shareholder notice  
 
    Change in substantial holding  
 
    Appendix 3B - shares issued on conversion of notes  
 
    Appendix 3B - allotment of rights issue underwriter shares  
 
    Notice under section 708A(5)(e)  
 
    Appendix 3B - allotment of rights issue shares  
 
    Neuren Appendix 4C December 2007  
 
    Results of Rights Issue  
 
    US Department of Defense Approves NNZ2566 Funding  
 
    Glypromate trial recruits 100th patient  
 
    Neuren Confirms Despatch of Rights Issue Offer Documents  
 
    Section 708AA Notice